Corporate Sponsors

Amgen

Amgen is a leading human therapeutics company in the biotechnology industry. For 25 years, the company has tapped the power of scientific discovery and innovation to dramatically improve people’s lives.

Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.

AstraZeneca

Our approach

Even as research and development continues to break boundaries in how we understand and fight cancer, there are still more than eight million lives lost every year to the disease.

At AstraZeneca, we are committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of four scientific platforms to help address unmet clinical needs in a host of cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death.

CHOC

CHOC was established to function as a group purchasing organization for POHMS members and to share any benefits derived from group purchasing activities.

CHOC selects a preferred vendor, based on a competitive bid process, to provide aggressive drug pricing, payment terms and a variety of related services eligible to CHOC member practices.  CHOC's current preferred vendor is McKesson Specialty Health. 

CHOC believes every practice has full control over their ability to buy whatever drugs they choose. CHOC’s goal is to assist members with making well-informed decisions at the best available price.

CHOC's vision is to provide an optimal drug-purchasing environment for Hematology Oncology practices.

Daiichi-Sankyo, Inc.

Takeda Oncology

TAKEDA ONCOLOGY (formerly known as MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY) endeavors to deliver novel medicines to cancer patients worldwide through our science, innovation and passion for improving patients’ lives. We know this mission is not an easy one but we are up to the task: we aspire to cure cancer.

Array Biopharma Inc

Array Today
Array markets in the United States BRAFTOVI^™ (encorafenib) capsules in combination with MEKTOVI^®(binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF^V600E or BRAF^V600K mutation as detected by an FDA-approved test.* Array's lead clinical programs, encorafenib and binimetinib, are being investigated in over 30 clinical trials across a number of solid tumor indications, including a Phase 3 trial in BRAF-mutant colorectal cancer. 

Values 
At Array, we embrace three core values that guide our day-to-day activities:

1. Integrity and transparency in what we do and how we do it
2. A sense of urgency and creativity in bringing benefit to patients
3. The knowledge to achieve our critical objectives

Astellas Pharma US INC

Merck

Novartis

Alexion

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D). As the leader in complement biology for over 20 years, Alexion focuses its research efforts on novel molecules and targets in the complement cascade, and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. 

Janssen Biotech

For more than 30 years, Janssen Biotech, Inc. has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease.

Built upon a rich legacy of innovative "firsts" Janssen Biotech, Inc. pursues innovative solutions in the therapeutic areas of immunology, oncology and nephrology. With the same unwavering passion for new challenges, we dedicate ourselves to delivering solutions for these disease states where unmet needs continue to exist.

Rooted in rich scientific collaborations and community-based relationships, we have access to some of the top minds in science today, allowing us to advance the treatment of patients through our innovative medicines. Our discoveries lead us not only to new treatments, but also to new ways to empower patients and expand their access to quality care – because we believe that changing lives for the better takes more than medicine.

We invite you to visit our sister companies, Janssen Pharmaceuticals, Inc. and Janssen Therapeutics, who share our vision of advancing patient care.

Sanofi-Genzyme Oncology

Sanofi's focus on patients has driven our historical and ongoing strategy to create long-term value by researching and delivering the best treatments. Sanofi’s oncology heritage has given us an extensive knowledge base that enriches our current research expertise. This experience encompasses a wide variety of cancer types, disease stages, patient populations, and patient needs. As a global healthcare company  focused on patient needs, we are committed to attacking cancer on all fronts.

Taiho Oncology Inc

Alexion Pharmaceuticals

AMAG Pharmaceuticals

Biologics Inc.

Boehringer Ingelheim Oncology

Coherus BIOSCIENCES

Eagle Pharmaceuticals

Eusa Pharma

Exelixis

GenPath

Guardant Health

Inform Diagnostics

Ipsen

Kyowa Kirin

Mylan Inc.

Onco 360, Oncology Pharmacy

Pfizer

Spectrum Pharmaceuticals

Syenos

Teva Oncology

Unlimited Systems